Zwitterionic polymer gel for enhanced topical skin healing
Cleragel™, a zwitterionic polymer gel by GelSana Therapeutics, offers advanced post-shave care and wound healing by reducing inflammation and bacterial adhesion. It promotes faster recovery and skin health through innovative macrophage modulation.
Overview
Cleragel™ is an innovative zwitterionic polymer gel developed by GelSana Therapeutics, designed for enhanced topical skin healing and post-shave care. This advanced gel leverages the unique properties of zwitterionic materials to conform to complex skin surfaces, evade foreign body responses, and resist bacterial adhesion. By modulating macrophage phenotypes, Cleragel™ reduces inflammation and supports tissue remodeling, thereby accelerating wound healing and enhancing overall skin health. Initial studies have demonstrated its effectiveness in diabetic wound healing and potential for consumer post-shave applications.
Technical specifications
Key features:
- Zwitterionic composition: Utilizes zwitterionic materials that resist foreign body responses and decrease pro-inflammatory cytokine expression.
- Macrophage modulation: Shifts macrophages from M1 to M2 phenotypes, promoting ECM remodeling and reducing inflammation.
- Bacterial resistance: Repels bacterial adhesion, maintaining a sterile environment on the skin.
- Flexible and conformable: Designed to stretch and conform to complex skin contours, ideal for sensitive skin applications.
Future developments:
- Development of a patch-based formulation for easy post-shave application.
- Potential for controlled drug delivery by incorporating active agents into the polymer.
- Planned in vitro studies to optimize mechanical properties and assess inflammation reduction and skin sensitization.
Technology readiness level
Cleragel™ has achieved a Technology Readiness Level (TRL) of 6, indicating that it has been validated in relevant environments and is progressing towards full-scale development. Future studies aim to optimize its properties for consumer use and further validate its efficacy through in vitro assessments.
About GelSana Therapeutics, Inc.
GelSana Therapeutics is a biomaterials company that specializes in developing advanced wound care solutions powered by proprietary zwitterionic polymer technology. Founded in 2020, the company engineers hydrogel-based products designed to address excess sustained inflammation, a primary barrier to natural healing in chronic wounds, surgical incisions, and burns. Their signature product, CleraFlex, is a stretchable, moldable wound dressing that creates a protective barrier to balance moisture, repel bacteria, and support the body’s natural healing cascade without triggering adverse immune responses. The dressing is designed to be highly adaptable, conforming to irregular wound geometries and providing a versatile solution for clinical application.
These technologies are intended to improve patient outcomes by accelerating healing, reducing the risk of complications such as infection and amputation, and simplifying the care process for healthcare providers. By focusing on the biological mechanisms of difficult-to-heal wounds, GelSana aims to replace conventional dressings with materials that actively support healing. The company, headquartered in Aurora, Colorado, works with clinical advisors and partners to translate academic research into viable clinical products, supported by funding from sources including the Department of Defense SBIR program and various venture capital initiatives.
Inquire about this partnering listing
Industry applications
delivered to your inbox.